{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:06:48Z","timestamp":1791936408218,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1189939"],"award-info":[{"award-number":["APP1189939"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1161198"],"award-info":[{"award-number":["APP1161198"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["MCRF21004"],"award-info":[{"award-number":["MCRF21004"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and primary peritoneal cancers (HGSC) has improved patient survival, resistance to PARP inhibitors frequently occurs. Preclinical and translational studies have identified multiple mechanisms of resistance; here we examined tumour samples collected from 26 women following treatment with PARP inhibitors as part of standard of care or their enrolment in clinical trials. Twenty-one had a germline or somatic <jats:italic>BRCA1\/2<\/jats:italic> mutation. We performed targeted sequencing of 63 genes involved in DNA repair processes or implicated in ovarian cancer resistance. We found that just three individuals had a  small-scale mutation as a definitive\u00a0resistance mechanism detected, having reversion mutations, while six had potential mechanisms of resistance detected, with alterations related to <jats:italic>BRCA1<\/jats:italic> function and mutations in <jats:italic>SHLD2<\/jats:italic>. This study indicates that mutations in genes related to DNA repair are detected in a minority of HGSC patients as genetic mechanisms of resistance. Future research into resistance in HGSC should focus on copy number, transcriptional and epigenetic aberrations, and the contribution of the tumour microenvironment.<\/jats:p>","DOI":"10.1038\/s41598-023-48153-x","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T04:08:58Z","timestamp":1702267738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"Nikki L.","family":"Burdett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelynne O.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahwan","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Fereday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AOCS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Management Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bowtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chenevix-Trench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"DeFazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gertig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Project and Data Managers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Traficante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fereday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Harrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sadkowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pandeya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Research Nurses and Assistants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Malt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vanden Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maidens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Nattress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. E.","family":"Chiew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stenlake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ashover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Corrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jayde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Galletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hendley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Alsop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Viduka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Bilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Glavinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Clinical and Scientific Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stuart-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rutovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Clingan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Glasgow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Proietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Braye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Otton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Begbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Baron-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Nevell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Valmadre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Camaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Crouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Beith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dalrymple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Links","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grygiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Byth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jaworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Papadimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Crandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Horwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Obermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Wyld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nicklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Davy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Oehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pierdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Challis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Robbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jobling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Manolitsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"McNealage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Susil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sumithran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Loughrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Waring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Billson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Neesham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. F.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McCartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Haviv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Purdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Zeps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"DeFazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D. L.","family":"Bowtell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"issue":"21","key":"48153_CR1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop, K., Fereday, S. & Meldrum, C. BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30(21), 2654 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"48153_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20(3), 764\u2013775 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"7353","key":"48153_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"CGAR Network","year":"2011","unstructured":"Network, C. G. A. R. Integrated genomic analyses of ovarian carcinoma. Nature 474(7353), 609\u2013615 (2011).","journal-title":"Nature"},{"issue":"1","key":"48153_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat. Commun. 12(1), 1\u201313 (2021).","journal-title":"Nat. Commun."},{"issue":"11","key":"48153_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41416-018-0274-8","volume":"119","author":"DR Hodgson","year":"2018","unstructured":"Hodgson, D. R. et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br. J. Cancer 119(11), 1401\u20131409 (2018).","journal-title":"Br. J. Cancer"},{"issue":"10","key":"48153_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"AR Chaudhuri","year":"2017","unstructured":"Chaudhuri, A. R. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18(10), 610\u2013621 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"11","key":"48153_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D\u2019Andrea, A. D. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 5(11), 1137\u20131154 (2015).","journal-title":"Cancer Discov."},{"issue":"2","key":"48153_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"48153_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15(8), 852\u2013861 (2014).","journal-title":"Lancet Oncol."},{"key":"48153_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(21)00531-3 (2021).","journal-title":"Lancet Oncol."},{"issue":"10106","key":"48153_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10106), 1949\u20131961 (2017).","journal-title":"Lancet"},{"issue":"25","key":"48153_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N.Engl. J. Med. 381(25), 2391\u20132402 (2019).","journal-title":"N.Engl. J. Med."},{"key":"48153_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fonc.2015.00169","volume":"5","author":"DJ VanderWeele","year":"2015","unstructured":"VanderWeele, D. J., Paner, G. P., Fleming, G. F. & Szmulewitz, R. Z. Sustained complete response to cytotoxic therapy and the PARP inhibitor veliparib in metastatic castration-resistant prostate cancer\u2013a case report. Front. Oncol. 5, 169 (2015).","journal-title":"Front. Oncol."},{"issue":"3","key":"48153_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.6004\/jnccn.2019.7378","volume":"18","author":"M Randall","year":"2020","unstructured":"Randall, M., Burgess, K., Buckingham, L. & Usha, L. Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion. J. Natl. Comprehens. Cancer Netw. 18(3), 223\u2013228 (2020).","journal-title":"J. Natl. Comprehens. Cancer Netw."},{"issue":"9","key":"48153_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","volume":"7","author":"O Kondrashova","year":"2017","unstructured":"Kondrashova, O. et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 7(9), 984\u2013998 (2017).","journal-title":"Cancer Discov."},{"issue":"9","key":"48153_CR16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall, J. et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 7(9), 1006\u20131017 (2017).","journal-title":"Cancer Discov."},{"issue":"12","key":"48153_CR17","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","volume":"35","author":"EL Christie","year":"2017","unstructured":"Christie, E. L. et al. Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J. Clin. Oncol. 35(12), 1274\u20131280 (2017).","journal-title":"J. Clin. Oncol."},{"key":"48153_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41588-023-01320-2","volume":"55","author":"NL Burdett","year":"2023","unstructured":"Burdett, N. L. et al. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat. Genet. 55, 437\u2013450 (2023).","journal-title":"Nat. Genet."},{"issue":"18","key":"48153_CR19","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1158\/1078-0432.CCR-21-0748","volume":"27","author":"SL Puhalla","year":"2021","unstructured":"Puhalla, S. L. et al. Relevance of platinum-free interval and BRCA reversion mutations for veliparib monotherapy after progression on carboplatin\/paclitaxel for gBRCA advanced breast cancer (BROCADE3 crossover). Clin. Cancer Res. 27(18), 4983\u20134993 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"48153_CR20","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","volume":"68","author":"EM Swisher","year":"2008","unstructured":"Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68(8), 2581\u20132586 (2008).","journal-title":"Cancer Res."},{"key":"48153_CR21","first-page":"313","volume":"2","author":"L Tobalina","year":"2020","unstructured":"Tobalina, L., Armenia, J., Irving, E., O\u2019Connor, M. & Forment, J. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Ann. Oncol. 2, 313 (2020).","journal-title":"Ann. Oncol."},{"issue":"9","key":"48153_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","volume":"7","author":"D Quigley","year":"2017","unstructured":"Quigley, D. et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of <em>BRCA2<\/em> reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 7(9), 999\u20131005 (2017).","journal-title":"Cancer Discov."},{"issue":"21","key":"48153_CR23","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt, B. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin. Cancer Res. 23(21), 6708\u20136720 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"48153_CR24","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.1200\/JCO.2022.40.16_suppl.5559","volume":"40","author":"N Lukashchuk","year":"2022","unstructured":"Lukashchuk, N. et al. BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer. J. Clin. Oncol. 40(16), 5559 (2022).","journal-title":"J. Clin. Oncol."},{"key":"48153_CR25","first-page":"523","volume":"54","author":"AG Waks","year":"2020","unstructured":"Waks, A. G. et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer. Ann. Oncol. 54, 523 (2020).","journal-title":"Ann. Oncol."},{"issue":"7716","key":"48153_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","volume":"560","author":"SM Noordermeer","year":"2018","unstructured":"Noordermeer, S. M. et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature 560(7716), 117\u2013121 (2018).","journal-title":"Nature"},{"issue":"1","key":"48153_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt, S. J. et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat. Commun. 9(1), 1\u201314 (2018).","journal-title":"Nat. Commun."},{"issue":"1","key":"48153_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-019-0442-y","volume":"22","author":"CS Clairmont","year":"2020","unstructured":"Clairmont, C. S. et al. TRIP13 regulates DNA repair pathway choice through REV7 conformational change. Nat. Cell Biol. 22(1), 87\u201396 (2020).","journal-title":"Nat. Cell Biol."},{"issue":"9","key":"48153_CR29","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","volume":"76","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. The BRCA1-\u039411q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Res. 76(9), 2778\u20132790 (2016).","journal-title":"Cancer Res."},{"issue":"3","key":"48153_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/path.3023","volume":"226","author":"E Kuhn","year":"2012","unstructured":"Kuhn, E. et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2014Evidence supporting the clonal relationship of the two lesions. J. Pathol. 226(3), 421\u2013426 (2012).","journal-title":"J. Pathol."},{"issue":"1","key":"48153_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221(1), 49\u201356 (2010).","journal-title":"J. Pathol."},{"issue":"10","key":"48153_CR32","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","volume":"10","author":"SJ Pettitt","year":"2020","unstructured":"Pettitt, S. J. et al. Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10(10), 1475\u20131488 (2020).","journal-title":"Cancer Discov."},{"issue":"6","key":"48153_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccr.2011.11.014","volume":"20","author":"R Drost","year":"2011","unstructured":"Drost, R. et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 20(6), 797\u2013809 (2011).","journal-title":"Cancer Cell"},{"issue":"2","key":"48153_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.annonc.2022.11.003","volume":"34","author":"S Labidi-Galy","year":"2023","unstructured":"Labidi-Galy, S. et al. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: Phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis. Ann. Oncol. 34(2), 152\u2013162 (2023).","journal-title":"Ann. Oncol."},{"issue":"8","key":"48153_CR35","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1172\/JCI87033","volume":"126","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. RING domain\u2013deficient BRCA1 promotes PARP inhibitor and platinum resistance. J. Clin. Investig. 126(8), 3145\u20133157 (2016).","journal-title":"J. Clin. Investig."},{"issue":"4","key":"48153_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","volume":"307","author":"KL Bolton","year":"2012","unstructured":"Bolton, K. L. et al. Association Between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307(4), 382\u2013389 (2012).","journal-title":"JAMA"},{"issue":"3","key":"48153_CR37","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","volume":"21","author":"FJ Candido-dos-Reis","year":"2015","unstructured":"Candido-dos-Reis, F. J. et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancerBRCA1\/2 mutation and ten-year survival in ovarian cancer. Clin. Cancer Res. 21(3), 652\u2013657 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"48153_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13530-6","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nat. Commun. 10(1), 1\u201312 (2019).","journal-title":"Nat. Commun."},{"issue":"42","key":"48153_CR39","doi-asserted-by":"publisher","first-page":"17041","DOI":"10.1073\/pnas.1305170110","volume":"110","author":"N Johnson","year":"2013","unstructured":"Johnson, N. et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc. Natl. Acad. Sci. 110(42), 17041\u201317046 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"48153_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41556-018-0140-1","volume":"20","author":"H Dev","year":"2018","unstructured":"Dev, H. et al. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat. Cell Biol. 20(8), 954 (2018).","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"48153_CR41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141(2), 243\u2013254 (2010).","journal-title":"Cell"},{"issue":"8","key":"48153_CR42","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/humu.20321","volume":"27","author":"X Wu","year":"2006","unstructured":"Wu, X., Dong, X., Liu, W. & Chen, J. Characterization of CHEK2 mutations in prostate cancer. Hum. Mutat. 27(8), 742\u2013747 (2006).","journal-title":"Hum. Mutat."},{"issue":"1","key":"48153_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2801","volume":"13","author":"L Calvez-Kelm","year":"2011","unstructured":"Calvez-Kelm, L. et al. Rare, evolutionarily unlikely missense substitutions in CHEK2contribute to breast cancer susceptibility: Results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res. 13(1), 1\u201312 (2011).","journal-title":"Breast Cancer Res."},{"issue":"2","key":"48153_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0921-8777(00)00002-1","volume":"459","author":"MA Brenneman","year":"2000","unstructured":"Brenneman, M. A., Weiss, A. E., Nickoloff, J. A. & Chen, D. J. XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat. Res.\/DNA Repair 459(2), 89\u201397 (2000).","journal-title":"Mutat. Res.\/DNA Repair"},{"issue":"18","key":"48153_CR45","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-21-0774","volume":"81","author":"K Nesic","year":"2021","unstructured":"Nesic, K. et al. Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma. Cancer Res. 81(18), 4709\u20134722 (2021).","journal-title":"Cancer Res."},{"issue":"7","key":"48153_CR46","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen, J. et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP InhibitorsTargeting ARID1A deficiency with PARP inhibitors. Cancer Discov. 5(7), 752\u2013767 (2015).","journal-title":"Cancer Discov."},{"issue":"3","key":"48153_CR47","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.celrep.2018.03.093","volume":"23","author":"H-M Hu","year":"2018","unstructured":"Hu, H.-M. et al. A quantitative chemotherapy genetic interaction map reveals factors associated with PARP inhibitor resistance. Cell Rep. 23(3), 918\u2013929 (2018).","journal-title":"Cell Rep."},{"issue":"1","key":"48153_CR48","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie, E. L. et al. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat. Commun. 10(1), 1295 (2019).","journal-title":"Nat. Commun."},{"issue":"7553","key":"48153_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"A-M Patch","year":"2015","unstructured":"Patch, A.-M. et al. Whole\u2013genome characterization of chemoresistant ovarian cancer. Nature 521(7553), 489\u2013494 (2015).","journal-title":"Nature"},{"issue":"2","key":"48153_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","volume":"9","author":"KK Lin","year":"2019","unstructured":"Lin, K. K. et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 9(2), 210\u2013219 (2019).","journal-title":"Cancer Discov."},{"issue":"8","key":"48153_CR51","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.cell.2021.03.009","volume":"184","author":"SC Dentro","year":"2021","unstructured":"Dentro, S. C. et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell 184(8), 2239\u201354.e39 (2021).","journal-title":"Cell"},{"issue":"1","key":"48153_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/path.4230","volume":"231","author":"A Bashashati","year":"2013","unstructured":"Bashashati, A. et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231(1), 21\u201334 (2013).","journal-title":"J. Pathol."},{"issue":"7","key":"48153_CR53","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ng.3573","volume":"48","author":"A McPherson","year":"2016","unstructured":"McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48(7), 758\u2013767 (2016).","journal-title":"Nat. Genet."},{"issue":"16","key":"48153_CR54","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"S Lheureux","year":"2020","unstructured":"Lheureux, S. et al. EVOLVE: A multicenter open-label single-arm clinical and translational phase ii trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin. Cancer Re. 26(16), 4206\u20134215 (2020).","journal-title":"Clin. Cancer Re."},{"key":"48153_CR55","first-page":"1","volume":"11","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2023","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature 11, 1\u20139 (2023).","journal-title":"Nature"},{"issue":"1","key":"48153_CR56","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1038\/s41467-023-39867-7","volume":"14","author":"P Smith","year":"2023","unstructured":"Smith, P. et al. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma. Nat. Commun. 14(1), 4387 (2023).","journal-title":"Nat. Commun."},{"issue":"11","key":"48153_CR57","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai, Z. et al. VarDict: A novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44(11), e108 (2016).","journal-title":"Nucleic Acids Res."},{"issue":"14","key":"48153_CR58","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: Accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs. Bioinformatics 28(14), 1811\u20131817 (2012).","journal-title":"Bioinformatics"},{"issue":"3","key":"48153_CR59","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22(3), 568\u2013576 (2012).","journal-title":"Genome Res."},{"issue":"12","key":"48153_CR60","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1101\/gr.222109.117","volume":"27","author":"DL Cameron","year":"2017","unstructured":"Cameron, D. L. et al. GRIDSS: Sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. Genome Res. 27(12), 2050\u20132060 (2017).","journal-title":"Genome Res."},{"issue":"1","key":"48153_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccell.2020.12.011","volume":"39","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Exploration of coding and non-coding variants in cancer using GenomePaint. Cancer Cell 39(1), 83-954.e4 (2021).","journal-title":"Cancer Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48153-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48153-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T16:05:04Z","timestamp":1702310704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48153-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["48153"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48153-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"26 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.dF declares receiving grant funding from AstraZeneca. D.D.L.B. reports research support grants from Roche-Genentech, AstraZeneca, and personal consulting fees from Exo Therapeutics, none of which are related to this work. No other authors report conflicts of interest relevant to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21884"}}